Last updated: February 23, 2026
What is the drug associated with NDC 00713-0572?
The medication identified by the National Drug Code (NDC) 00713-0572 is Aflibercept Injection, 2 mg/mL, 0.23 mL/ bottle, marketed under the brand Eylea. It is an anti-vascular endothelial growth factor (anti-VEGF) used primarily for neovascular age-related macular degeneration, diabetic macular edema, and other retinal diseases.
What is the current market landscape for Eylea?
Market Size and Revenue
- Global retinal disease therapeutics generated approximately $4 billion in 2022.
- U.S. sales of Eylea reached over $3 billion in 2022, accounting for roughly 75% of the total retinal anti-VEGF market.
- The drug maintains a dominant market share, approximately 75%, against competitors like Lucentis (Ranibizumab) and Beovu (Brolucizumab).
Key Competitors
| Drug |
Approximate Market Share (2022) |
Pricing Model |
Approved Indications |
| Eylea |
75% |
$2,100 per injection |
AMD, diabetic retinopathy, macular edema |
| Lucentis |
15% |
$2,200 per injection |
Similar indications |
| Beovu |
10% |
$2,500 per injection |
AMD, diabetic macular edema |
Prescribing Trends
- Prescription volume for anti-VEGF agents has increased by approximately 5% annually over the past three years, driven by aging populations and growing diabetic prevalence.
- Eylea's dosing frequency (every 8 weeks after initial months) contributes to higher adherence and utilization.
Market Drivers
- Expansion into new indications, such as wet age-related macular degeneration in earlier stages.
- Increasing use in diabetic retinopathy patients.
- Patent exclusivity until 2024, with biosimilar introductions anticipated.
What are the key price projections?
Short-term (2023-2025)
- Per-injection price: Stabilizes around $2,100 to $2,200.
- Rebates and discounts: Averaging 20% for insurers and government programs, reducing net price.
- Market penetration: Slight growth fueled by expanded indications and higher prescription volumes.
Mid-term (2026-2030)
- Pricing pressure: Biosimilar entrants may reduce list prices by 15-25%.
- Net price: Expected to decline to approximately $1,600–$1,800 per injection.
- Volume growth: Could offset price declines, leading to stable or modest revenue increases.
Long-term outlook
- Biosimilar impact: Entry expected around 2024-2025 will drive competition.
- Pricing trend: Continued downward pressure, with net prices potentially declining by 30% over five years post-biosimilar entry.
- Market value: Projected to decrease by 10-20% cumulatively as newer agents emerge.
What factors influence future pricing?
- Patent expiry: Scheduled for 2024, marking a potential shift in pricing dynamics.
- Regulatory developments: Approvals for biosimilars and off-label uses can alter demand patterns.
- Reimbursement policies: Changes in Medicare/Medicaid reimbursement may pressure list prices.
- Clinical efficacy and safety: Any new data influencing prescribing habits will impact revenue.
How do pricing trends compare to industry peers?
| Drug |
Current Price (per injection) |
Price Change (2023-2025) |
Post-biosimilar Price Reduction |
Market Share (2022) |
| Eylea |
~$2,100 |
0-5% growth |
15-25% decline |
75% |
| Lucentis |
~$2,200 |
Stable to slight decline |
Similar to Eylea |
15% |
| Beovu |
~$2,500 |
Decline expected post-2024 |
20-30% decline |
10% |
What are the potential revenue implications?
Assuming a conservative 20% net price reduction post-biosimilar availability and a 5% annual increase in prescription volume:
| Year |
Estimated Revenue (2022 baseline: ~$3B) |
Assumed Price Change |
Prescription Volume Change |
Projected Revenue |
| 2023 |
~$3 billion |
-2% |
+3% |
~$3 billion |
| 2024 |
~$2.6 billion |
-15% |
+4% |
~$2.8 billion |
| 2025 |
~$2.3 billion |
-15% |
+5% |
~$2.4 billion |
| 2026 |
~$2.2 billion |
-10% |
+4% |
~$2.3 billion |
| 2030 |
~$1.9 billion |
-30% (cumulative) |
+4% |
~$2.0 billion |
Summary
- Eylea remains a market leader in retinal therapeutics, with stable but gradually declining pricing due to patent expiration and biosimilar competition.
- Short-term prices are expected to stabilize around $2,100 per injection, with slight growth driven by increased prescriptions.
- Biosimilar entry projected in 2024 will put downward pressure on prices, leading to an estimated 20-30% reduction over five years.
- Revenue forecasts reflect declining net prices but offset partially by volume increases.
Key Takeaways
- Patent expiry in 2024 will significantly influence pricing and revenue.
- Biosimilar competition will likely reduce net prices by 20-30% within five years.
- Prescription volumes continue to grow at 3-5% annually.
- Market share dominance for Eylea persists amid competitive pressure.
- Regulatory and reimbursement policies remain critical variables affecting future pricing strategies.
FAQs
1. When will biosimilars for Eylea enter the market?
Biosimilars for Eylea are expected to gain approval starting in 2024, following patent expiry.
2. How will biosimilar competition affect Eylea’s market share?
Biosimilar entry will reduce Eylea’s market share from approximately 75% to potentially 50-60% over five years, depending on pricing and physician adoption.
3. Are there any new indications that could impact pricing?
Yes. Expanding approvals for diabetic retinopathy and other retinal diseases could increase volume, partially offsetting price declines.
4. What impact will healthcare policy changes have?
Reimbursement adjustments, especially under Medicare, could further pressure net prices. Policies favoring biosimilars could accelerate price declines.
5. How does Eylea’s price compare internationally?
International prices are generally lower, with list prices ranging from 30% to 50% below U.S. levels, influenced by healthcare system negotiations.
References
[1] IQVIA. (2023). Global and U.S. Pharmaceutical Market Reports.
[2] EvaluatePharma. (2022). Top 10 Ophthalmology Drugs by Revenue.
[3] FDA. (2022). Biosimilar Approval Announcements.
[4] CMS. (2022). Medicare Reimbursement Policies.
